$0.00
−6.67%Nov 3, 2026, 12:00 UTC
The U.S. Food and Drug Administration cleared Pasithea Therapeutics’ IND application for a randomized, placebo-controlled Phase 2 trial of PAS-004 in patients with NF1-associated cutaneous neurofibromas.
Source:Oct 23, 2026, 13:15 UTC
Pasithea Therapeutics Corp. reported clinical data showing prolonged stable disease in patients receiving PAS-004 in a Phase 1 advanced cancer study, with four patients treated for more than 300 days and two for more than 500 days; the company also described the drug’s safety profile as favorable.
Source:Sep 14, 2026, 11:00 UTC
Pasithea Therapeutics announced it will present initial Part A clinical data from its ongoing Phase 1/1b trial of PAS-004 in adults with NF1 at the 2026 European Neurofibromatosis Conference in Vienna, Austria, on November 12-14, 2026.
Source:Jun 2, 2026, 11:02 UTC
The FDA granted Orphan Drug Designation to Pasithea Therapeutics' PAS-004 for the treatment of ALS.
Source: